Joe Bonaccorso Sells 25,461 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insider Joe Bonaccorso sold 25,461 shares of Verrica Pharmaceuticals stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total transaction of $179,754.66. Following the transaction, the insider now directly owns 106,931 shares in the company, valued at $754,932.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Verrica Pharmaceuticals Stock Performance

VRCA opened at $7.25 on Friday. The firm’s 50 day moving average is $8.03 and its 200-day moving average is $6.77. Verrica Pharmaceuticals Inc. has a 52-week low of $2.86 and a 52-week high of $11.41. The company has a current ratio of 3.17, a quick ratio of 3.04 and a debt-to-equity ratio of 29.58.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.10. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $2.70 million. Verrica Pharmaceuticals had a negative net margin of 905.83% and a negative return on equity of 229.26%. On average, equities research analysts predict that Verrica Pharmaceuticals Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VRCA has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on shares of Verrica Pharmaceuticals from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. HC Wainwright lifted their price objective on shares of Verrica Pharmaceuticals from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th.

Institutional Trading of Verrica Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in VRCA. Perceptive Advisors LLC increased its stake in shares of Verrica Pharmaceuticals by 40.9% in the fourth quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock worth $51,966,000 after buying an additional 2,060,199 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in shares of Verrica Pharmaceuticals by 35.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock worth $29,280,000 after buying an additional 1,045,935 shares during the last quarter. BML Capital Management LLC increased its stake in shares of Verrica Pharmaceuticals by 20.0% in the fourth quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock worth $1,318,000 after buying an additional 30,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Verrica Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after buying an additional 7,609 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Verrica Pharmaceuticals by 8.1% in the second quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock worth $428,000 after buying an additional 4,393 shares during the last quarter. Institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.